Sign inCreate account

Report workspace tools

NCT06076772NOT_YET_RECRUITINGanonymous

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Sponsor

Source record

Assiut University

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Palbociclib-induced neutropenia in metastatic breast cancer patients

Indication / condition

AI-normalized

Metastatic Breast Cancer

Intervention

Source record

Palbociclib

Source & freshness

Source record

NCT ID

NCT06076772

Original source

ClinicalTrials.gov

Source last updated

Oct 11, 2023

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06076772

Title

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Sponsor

Assiut University

Status

NOT_YET_RECRUITING

Phase

Observational

Condition raw

Metastatic Breast Cancer

Condition normalized

Metastatic Breast Cancer

Modality raw

Metastatic Breast Cancer

Modality normalized

monoclonal antibody

Target raw

Palbociclib-induced neutropenia in metastatic breast cancer patients

Target normalized

Palbociclib-induced neutropenia in metastatic breast cancer patients

Interventions

Palbociclib

Public preview

Source record

This study aims to assess the risk factors and treatment outcomes associated with neutropenia induced by Palbociclib in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study will evaluate progression-free survival (PFS) and overall survival (OS) over a two-year period, providing insights into the pharmacodynamics of Palbociclib and potential dose optimization strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06076772

Status

NOT_YET_RECRUITING

Phase

Observational

Sponsor

Assiut University

Executive brief

Investment-Ready Snapshot

This study aims to assess the risk factors and treatment outcomes associated with neutropenia induced by Palbociclib in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study will evaluate progression-free survival (PFS) and overall survival (OS) over a two-year period, providing insights into the pharmacodynamics of Palbociclib and potential dose optimization strategies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 11, 2023
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06076772

Indication

Metastatic Breast Cancer

Modality

monoclonal antibody

Target

Palbociclib-induced neutropenia in metastatic breast cancer patients

Intervention

Palbociclib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.